Cardiol Therapeutics (TSE:CRDL) Sets New 1-Year Low – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as C$1.57 and last traded at C$1.70, with a volume of 87404 shares changing hands. The stock had previously closed at C$1.73.

Cardiol Therapeutics Trading Down 4.6 %

The company has a debt-to-equity ratio of 1.59, a quick ratio of 6.84 and a current ratio of 2.49. The company has a market cap of C$136.91 million, a PE ratio of -3.24 and a beta of 0.70. The stock has a fifty day moving average of C$1.88 and a 200-day moving average of C$2.34.

Insider Activity at Cardiol Therapeutics

In other Cardiol Therapeutics news, Director David Elsley purchased 40,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was acquired at an average price of C$1.88 per share, for a total transaction of C$75,072.00. Also, Senior Officer Guillermo Torre acquired 17,240 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was purchased at an average cost of C$1.81 per share, for a total transaction of C$31,277.77. Insiders have acquired 86,140 shares of company stock valued at $161,456 in the last ninety days. Corporate insiders own 4.57% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.